NTLA logo

Intellia Therapeutics, Inc. (NTLA) Cash From Financing

Annual CFF:

$185.75M+$55.42M(+42.53%)
December 31, 2024

Summary

  • As of today, NTLA annual cash from financing is $185.75 million, with the most recent change of +$55.42 million (+42.53%) on December 31, 2024.
  • During the last 3 years, NTLA annual cash from financing has fallen by -$550.94 million (-74.79%).
  • NTLA annual cash from financing is now -74.79% below its all-time high of $736.69 million, reached on December 31, 2021.

Performance

NTLA Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNTLAcash flow metrics

Quarterly CFF:

$114.86M+$100.20M(+683.90%)
September 30, 2025

Summary

  • As of today, NTLA quarterly cash from financing is $114.86 million, with the most recent change of +$100.20 million (+683.90%) on September 30, 2025.
  • Over the past year, NTLA quarterly cash from financing has increased by +$32.66 million (+39.74%).
  • NTLA quarterly cash from financing is now -82.82% below its all-time high of $668.68 million, reached on September 30, 2021.

Performance

NTLA Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNTLAcash flow metrics

TTM CFF:

$131.83M+$32.66M(+32.94%)
September 30, 2025

Summary

  • As of today, NTLA TTM cash from financing is $131.83 million, with the most recent change of +$32.66 million (+32.94%) on September 30, 2025.
  • Over the past year, NTLA TTM cash from financing has dropped by -$158.09 million (-54.53%).
  • NTLA TTM cash from financing is now -86.39% below its all-time high of $968.50 million, reached on September 30, 2021.

Performance

NTLA TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNTLAcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

NTLA Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+42.5%+39.7%-54.5%
3Y3 Years-74.8%+379.0%+65.9%
5Y5 Years+143.0%+10000.0%-16.2%

NTLA Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-74.8%+42.5%-77.3%>+9999.0%-77.4%+65.9%
5Y5-Year-74.8%+143.0%-82.8%>+9999.0%-86.4%+65.9%
All-TimeAll-Time-74.8%+1357.8%-82.8%+6295.1%-86.4%>+9999.0%

NTLA Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
$114.86M(+683.9%)
$131.83M(+32.9%)
Jun 2025
-
$14.65M(>+9900.0%)
$99.16M(-21.1%)
Mar 2025
-
$0.00(-100.0%)
$125.75M(-32.3%)
Dec 2024
$185.75M(+42.5%)
$2.32M(-97.2%)
$185.75M(-35.9%)
Sep 2024
-
$82.19M(+99.3%)
$289.91M(+27.8%)
Jun 2024
-
$41.25M(-31.2%)
$226.82M(+20.6%)
Mar 2024
-
$59.99M(-43.7%)
$188.09M(+44.3%)
Dec 2023
$130.32M(-77.6%)
$106.48M(+457.4%)
$130.32M(-75.4%)
Sep 2023
-
$19.10M(+659.2%)
$529.60M(-0.9%)
Jun 2023
-
$2.52M(+13.3%)
$534.48M(-0.6%)
Mar 2023
-
$2.22M(-99.6%)
$537.86M(-7.7%)
Dec 2022
$582.96M(-20.9%)
$505.76M(+2009.4%)
$582.96M(+633.5%)
Sep 2022
-
$23.98M(+306.7%)
$79.47M(-89.0%)
Jun 2022
-
$5.89M(-87.5%)
$724.17M(-0.2%)
Mar 2022
-
$47.32M(+1975.4%)
$725.41M(-1.5%)
Dec 2021
$736.69M(+98.2%)
$2.28M(-99.7%)
$736.69M(-23.9%)
Sep 2021
-
$668.68M(+9274.5%)
$968.50M(+222.4%)
Jun 2021
-
$7.13M(-87.8%)
$300.42M(-29.4%)
Mar 2021
-
$58.59M(-75.0%)
$425.51M(+14.5%)
Dec 2020
$371.78M
$234.09M(>+9900.0%)
$371.78M(+136.4%)
Sep 2020
-
$597.00K(-99.5%)
$157.25M(-22.6%)
Jun 2020
-
$132.22M(+2618.4%)
$203.05M(+162.7%)
DateAnnualQuarterlyTTM
Mar 2020
-
$4.86M(-75.1%)
$77.30M(+1.1%)
Dec 2019
$76.43M(+90.1%)
$19.56M(-57.8%)
$76.43M(-12.2%)
Sep 2019
-
$46.40M(+617.0%)
$87.03M(+103.3%)
Jun 2019
-
$6.47M(+61.8%)
$42.81M(+14.2%)
Mar 2019
-
$4.00M(-86.7%)
$37.50M(-6.8%)
Dec 2018
$40.22M(-71.9%)
$30.16M(+1283.6%)
$40.22M(-73.6%)
Sep 2018
-
$2.18M(+88.7%)
$152.17M(+1.2%)
Jun 2018
-
$1.16M(-82.8%)
$150.36M(+0.5%)
Mar 2018
-
$6.72M(-95.3%)
$149.65M(+4.7%)
Dec 2017
$142.98M(-14.5%)
$142.12M(>+9900.0%)
$142.98M(>+9900.0%)
Sep 2017
-
$371.00K(-16.8%)
$1.13M(+202.3%)
Jun 2017
-
$446.00K(+848.9%)
-$1.10M(-100.7%)
Mar 2017
-
$47.00K(-82.0%)
$168.55M(+0.7%)
Dec 2016
$167.30M(+138.0%)
$261.00K(+114.1%)
$167.30M(+0.4%)
Sep 2016
-
-$1.85M(-101.1%)
$166.59M(-29.2%)
Jun 2016
-
$170.09M(>+9900.0%)
$235.16M(+263.1%)
Mar 2016
-
-$1.20M(-162.1%)
$64.77M(-7.9%)
Dec 2015
$70.29M(+451.6%)
-$456.00K(-100.7%)
$70.29M(-0.6%)
Sep 2015
-
$66.72M(>+9900.0%)
$70.74M(+1656.3%)
Jun 2015
-
-$300.00K(-106.9%)
$4.03M(-6.9%)
Mar 2015
-
$4.33M
$4.33M
Dec 2014
$12.74M
-
-

FAQ

  • What is Intellia Therapeutics, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Intellia Therapeutics, Inc.?
  • What is Intellia Therapeutics, Inc. annual cash from financing year-on-year change?
  • What is Intellia Therapeutics, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Intellia Therapeutics, Inc.?
  • What is Intellia Therapeutics, Inc. quarterly cash from financing year-on-year change?
  • What is Intellia Therapeutics, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Intellia Therapeutics, Inc.?
  • What is Intellia Therapeutics, Inc. TTM cash from financing year-on-year change?

What is Intellia Therapeutics, Inc. annual cash from financing?

The current annual cash from financing of NTLA is $185.75M

What is the all-time high annual cash from financing for Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. all-time high annual cash from financing is $736.69M

What is Intellia Therapeutics, Inc. annual cash from financing year-on-year change?

Over the past year, NTLA annual cash from financing has changed by +$55.42M (+42.53%)

What is Intellia Therapeutics, Inc. quarterly cash from financing?

The current quarterly cash from financing of NTLA is $114.86M

What is the all-time high quarterly cash from financing for Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. all-time high quarterly cash from financing is $668.68M

What is Intellia Therapeutics, Inc. quarterly cash from financing year-on-year change?

Over the past year, NTLA quarterly cash from financing has changed by +$32.66M (+39.74%)

What is Intellia Therapeutics, Inc. TTM cash from financing?

The current TTM cash from financing of NTLA is $131.83M

What is the all-time high TTM cash from financing for Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. all-time high TTM cash from financing is $968.50M

What is Intellia Therapeutics, Inc. TTM cash from financing year-on-year change?

Over the past year, NTLA TTM cash from financing has changed by -$158.09M (-54.53%)
On this page